Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).

被引：0
|
作者：
Cheng, Ann-Lii
Cornelio, Gerardo H.
Shen, Lin
Price, Timothy Jay
Yang, Tsai-Shen
Chung, Ik-Joo
Dai, Guanghai
Lin, Jen-Kou
Sharma, Atul
Yeh, Kun-Huei
Ma, Brigette
Zaatar, Adel
Guan, Zhongzhen
Masood, Nehal
Srimuninnimit, Vichien
Yau, Thomas Cheung
Sarholz, Barbara
Lim, Robert S. C.
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] San Juan De Dios Hosp, Pasay City, Philippines
[3] Peking Univ, Canc Hosp, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China
[4] Queen Elizabeth Hosp, Adelaide, SA, Australia
[5] Chang Gung Mem Hosp, Taoyuan, Taiwan
[6] Chonnam Natl Univ, Hawsun Hosp, Hwasuneup, South Korea
[7] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[8] Taipei Vet Gen Hosp, Taipei, Taiwan
[9] All India Inst Med Sci, New Delhi, India
[10] Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China
[11] Mt Miriam Canc Hosp, George Town, Malaysia
[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
[13] Aga Khan Univ & Hosp, Karachi, Pakistan
[14] Siriraj Hosp, Bangkok, Thailand
[15] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[16] Merck KGaA, Darmstadt, Germany
[17] Natl Univ Hlth Syst, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14501
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
    Barroso, S. A.
    Sanches, E.
    Ferreira, M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)
    Hazama, Shoichi
    Maeda, Hiromichi
    Iwamoto, Shigeyoshi
    Kim, Ho Min
    Takemoto, Hiroyoshi
    Kobayashi, Kenji
    Sakamoto, Junichi
    Nagata, Naoki
    Oba, Koji
    Mishima, Hideyuki
    Clinical Colorectal Cancer, 2016, 15 (04) : 329 - 336
  • [23] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
    Brodowicz, T.
    Ciuleanu, T. E.
    Radosavljevic, D.
    Shacham-Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Mrsic-Krmpotic, Z.
    Dank, M.
    Purkalne, G.
    Messinger, D.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1769 - 1777
  • [24] A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Ciuleanu, T. E.
    Kurteva, G.
    Ocvirk, J.
    Beslija, S.
    Koza, I.
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Scheithauer, W.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Asmis, Timothy R.
    Goel, Rakesh
    Goodwin, Rachel Anne
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkaine, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] CETUXIMAB WEEKLY (Q1W) VERSUS EVERY TWO WEEKS (Q2W) PLUS FOLFOX4 AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC)
    Ciuleanu, Tudor
    Nikolic, Vladimir
    Shacham-Shmueli, Einat
    Vrbanec, Damir
    Plate, Signe
    Mrsic-Krmpotic, Zrinka
    Kahan, Zsuzsanna
    Purkalne, Gunta
    Brodowicz, Thomas
    Zielinski, Christoph
    ANNALS OF ONCOLOGY, 2011, 22 : v22 - v22
  • [29] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkalne, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [30] Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
    Kasper, Stefan
    Foch, Caroline
    Messinger, Diethelm
    Esser, Regina
    Lamy, Francois-Xavier
    Rothe, Vivien
    Chen, Wenfeng
    Cheng, Ann-Lii
    Rouyer, Magali
    Brodowicz, Thomas
    Zielinski, Christoph
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 291 - 301
12345